TissueGene Inc. is gearing to launch an initial public offering in South Korea to finance a Phase III US clinical trial of Invossa, its first-in-class cell and gene therapy drug. Invossa was approved by South Korean authorities in July making it the country's first gene therapy and the world’s first allogeneic cell mediated gene therapy for degenerative osteoarthritis.
Spotlight On TissueGene’s Upcoming Korea IPO
Regenerative drug company TissueGene’s proposed IPO in South Korea is drawing keen interest, coming close on the heels of the recent approval of its novel osteoarthritis drug in the country. Success of the IPO will be crucial for the company to proceed with a Phase III US study of the drug.
More from Business
• By
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.
• By
The German firm’s chairman, Hubertus von Baumbach, is adopting a ‘wait-and-see’ approach to the threat of pharma tariffs.
• By
Trump announced a 26% reciprocal tariff on India but a country-agnostic exemption of pharmaceuticals implies that the interests of Indian firms and the US consumer are protected for now. What is Indian pharma’s business exposure and what is domestic industry saying?
• By
Industry lobbied for pharmaceuticals to be exempt from Trump’s sweeping US tariffs and the effort appears to have paid off. J&J, Lilly and Merck & Co. even got shout outs.
More from Scrip
• By
With new Phase II data, Edgewise asserted that EDG-7500, a sarcomere modulator, could offer better efficacy and safety than cardiac myosin inhibitors in hypertrophic cardiomyopathy.
• By
The company closed a $150m series C funding round shortly after opening the second part of its Phase I/II study of ATSN-201 and partnering with a Nippon Shinyaku on ATSN-101.
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.